Nishimura H, Simpson I A
Metabolism and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD 20892.
Biochem J. 1994 Aug 15;302 ( Pt 1)(Pt 1):271-7. doi: 10.1042/bj3020271.
Staurosporine, a widely used protein kinase C inhibitor, completely inhibited both phorbol 12-myristate 13-acetate (PMA)- and insulin-stimulated glucose transport activity in isolated rat adipocytes. The inhibition was non-competitive and was attributed to a blockade of the PMA- and insulin-induced translocation of both GLUT1 and GLUT4 glucose transporters. The PMA-stimulated glucose transport activity was more sensitive to inhibition by staurosporine than was insulin-stimulated transport activity (PMA, IC50 = 1.1 +/- 0.1 microM; insulin, IC50 = 6.4 +/- 0.7 microM; P < 0.05, n = 3). At 1 microM staurosporine the insulin-sensitivity was decreased, i.e. EC50 increased from 0.12 nM to 5.4 nM, but the maximum response to insulin and the time course for stimulation were unaffected. At 6 microM staurosporine the insulin-sensitivity was further decreased, the maximal stimulation was decreased by 25%, and the apparent half-time for stimulation was extended from 2.5 min in control cells to 9.4 min. Staurosporine (30 microM) was able to block insulin's ability to stimulate glucose transport, whether added before or after insulin, by a mechanism that did not alter the rate of GLUT4 internalization. In intact adipose cells, staurosporine (30 microM) induced a slight (30%) decrease in the maximal insulin-induced receptor autophosphorylation and a similar decrease in the tyrosine phosphorylation of pp60 and pp160 (insulin-receptor substrate-1: 'IRS-1'), but was without effect on insulin binding to its receptor. Conversely, staurosporine induced a concentration-dependent inhibition of the constitutively tyrosine-phosphorylated (pp120) protein and of an insulin-stimulated protein pp53 in the cytosol. The locus of staurosporine's action appears to be distal from the initial insulin-receptor signalling, at a step that regulates the specific translocation of the glucose transporters to the plasma membranes.
星形孢菌素是一种广泛使用的蛋白激酶C抑制剂,它能完全抑制佛波酯12 -肉豆蔻酸酯13 -乙酸酯(PMA)和胰岛素刺激的离体大鼠脂肪细胞中的葡萄糖转运活性。这种抑制是非竞争性的,归因于对PMA和胰岛素诱导的GLUT1和GLUT4葡萄糖转运体转位的阻断。PMA刺激的葡萄糖转运活性比胰岛素刺激的转运活性对星形孢菌素的抑制更敏感(PMA,IC50 = 1.1±0.1微摩尔;胰岛素,IC50 = 6.4±0.7微摩尔;P < 0.05,n = 3)。在1微摩尔星形孢菌素存在时,胰岛素敏感性降低,即EC50从0.12纳摩尔增加到5.4纳摩尔,但对胰岛素的最大反应和刺激的时间进程未受影响。在6微摩尔星形孢菌素存在时,胰岛素敏感性进一步降低,最大刺激降低25%,刺激的表观半衰期从对照细胞中的2.5分钟延长至9.4分钟。星形孢菌素(30微摩尔)能够阻断胰岛素刺激葡萄糖转运的能力,无论在胰岛素之前还是之后添加,其机制不会改变GLUT4内化的速率。在完整的脂肪细胞中,星形孢菌素(30微摩尔)使最大胰岛素诱导的受体自身磷酸化轻微降低(30%),并且使pp60和pp160(胰岛素受体底物-1:“IRS-1”)的酪氨酸磷酸化有类似程度的降低,但对胰岛素与其受体的结合没有影响。相反,星形孢菌素诱导细胞溶质中组成型酪氨酸磷酸化的(pp120)蛋白和胰岛素刺激的pp53蛋白产生浓度依赖性抑制。星形孢菌素的作用位点似乎远离初始的胰岛素受体信号传导,处于调节葡萄糖转运体向质膜特异性转位的步骤。